DrugCentral: online drug compendium
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
DrugCentral (http://drugcentral.org) is an open-access online drug compendium. DrugCentral integrates structure, bioactivity, regulatory, pharmacologic actions and indications for active pharmaceutical ingredients approved by FDA and other regulatory agencies. Monitoring of regulatory agencies for new drugs approvals ensures the resource is up-to-date. DrugCentral integrates content for active ingredients with pharmaceutical formulations, indexing drugs and drug label annotations, complementing similar resources available online. Its complementarity with other online resources is facilitated by cross referencing to external resources. At the molecular level, DrugCentral bridges drug-target interactions with pharmacological action and indications. The integration with FDA drug labels enables text mining applications for drug adverse events and clinical trial information. Chemical structure overlap between DrugCentral and five online drug resources, and the overlap between DrugCentral FDA-approved drugs and their presence in four different chemical collections, are discussed. DrugCentral can be accessed via the web application or downloaded in relational database format.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are 217 drugs annotated in DrugCentral10 as acting through 125 (T) ion channels for the MoA9.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chemical structures were manually assigned to 140 of the latest veterinary drugs, and molecular descriptors and structure depictions were computed per DrugCentral workflow (1).”
From DrugCentral 2023 extends human clinical data and integrates veterinary drugs (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“DrugCentral has been a public digital database aggregating drug information since 2016 (1).”
From DrugCentral 2023 extends human clinical data and integrates veterinary drugs (2023) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
KEGG for integration and interpretation of large-scale molecular data sets
Kanehisa, M., Goto, S., Sato, Y., Furumichi, M., & Tanabe, M. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr988 · Cited by 4,848 · cited 2×
“The following resources matched our above inclusion criteria: the ChEMBL database (1), the Guide to Pharmacology (2) and KEGG Drug (3).”
BackgroundMethodThe unified medical language system (UMLS): integrating biomedical terminology
Bodenreider, O. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh061 · Cited by 4,356
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427 · cited 1×
“) to which the API or its active metabolite binds directly, to exert the therapeutic drug action (22).”
BackgroundSelf-citationDrugBank 4.0: shedding new light on drug metabolism
Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1068 · Cited by 1,993 · cited 10×
“The overlap matrix was computed for DrugCentral, in comparison with the following drugfocused resources: the NIH Center for Chemical Genomics (NCGC) pharmaceutical collection (11), DrugBank (12), the IDAAPM database (13), the phase 4 drugs subset from the ChEMBL 21 release (1) and the e-Drug3D database (14).”
MethodInfluentialThe ChEMBL bioactivity database: an update
Bento, A. P., Gaulton, A., Hersey, A., Bellis, L. J., Chambers, J., Davies, M., Krüger, F. A., Light, Y., Mak, L., McGlinchey, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1031 · Cited by 1,492 · cited 5×
“Mechanism of action annotations in DrugCentral are aggregated from several expert curated resources: ChEMBL database (1), Guide to Pharmacology (2), KEGG Drug (3), as well as manual curations extracted from drug labels and literature.”
BackgroundMethodInfluentialThe SIDER database of drugs and side effects
Kuhn, M., Letunic, I., Jensen, L. J., & Bork, P. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1075 · Cited by 1,451 · cited 3×
“Drug adverse events from FDA AERS database (https://open.fda.gov/) and SIDER (21) will be used to enhance the drug safety profile of existing drug reports.”
BackgroundSouthan, C., Sharman, J. L., Benson, H. E., Faccenda, E., Pawson, A. J., Alexander, S. P. H., Buneman, O. P., Davenport, A. P., McGrath, J. C., Peters, J. A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1037 · Cited by 1,035 · cited 3×
“Quantitative bioactivity data are aggregated from multiple sources including: ChEMBLDb (1) (58.73% of the records); DrugMatrix (23) (15.95%); WOMBAT-PK (24) (13.9%); Guide to Pharmacology (2) (5.29%); PDSP (25) (3.41%); scientific literature (2.35%); and drug labels (0.36%), respectively.”
BackgroundMethodInfluentialCalculating log Poct from structures
Leo, A. J. (1993) · Chemical Reviews · doi:10.1021/cr00020a001 · Cited by 695
Dalby, A., Nourse, J. G., Hounshell, W. D., Gushurst, A. K. I., Grier, D. L., Leland, B. A., & Laufer, J. (1992) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci00007a012 · Cited by 642 · cited 1×
“A multistep manual curation and validation process was employed to collect, record and store correct chemical information for API molecular structures in the MDL (‘Molecular Design Limited’) MOL format (8).”
Method
Cited by
Items 301–336 of 336
BRDKRM: An Explainable Framework for Disease Modifying Drug IdentificationPreprint
Chanda, A., Dey, A., Chakraborty, M., Maulik, U. B., & Bandyopadhyay, S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.24.614653
Kaur, R. P., & Manjh, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95502-7.00157-3
SmartGraph API: Programmatic Knowledge Mining in Network-Pharmacology Setting
Zahoránszky-Köhalmi, G., Walker, B., Miller, N., Yang, B., Penna, D. V. L., Maine, J., Sheils, T. K., Wang, K. W., King, J. P., Sidky, H., et al. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00789
Self-citationDrug Repurposing Through Molecular Docking
Tripathi, R. K. P. (2025) · IGI Global eBooks · doi:10.4018/979-8-3693-5598-5.ch009
Akçit, E. T., & Şimşek, E. (2025) · Journal of Balkan Science and Technology · doi:10.55848/jbst.2025.09
Bernabé, C. H., Zwart, R., Perdomo-Quinteiro, P., Jacobsen, A., Sales, T. P., Queralt-Rosiñach, N., Wolstencroft, K., Santos, L. O. B. D. S., Mons, B., & Roos, M. (2025) · Lecture notes in computer science · doi:10.1007/978-3-031-94571-7_17
Lichtenberg, F. R. (2025) · Econometrics · doi:10.3390/econometrics13030025
Construction of the Veterinary DrugBank and Drug Repurposing
Tian, Q., Wang, D., Zhang, Y., Zheng, Y., Luo, L., Huang, Z., Li, J., Wang, F., & Wei, D. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00507 · Cited by 1
Galea, D. (2019) · Spiral (Imperial College London) · doi:10.25560/83109
Liu, X., Zhang, W., Tong, X., Zhong, F., Li, Z., Xiong, Z., Xiong, J., Wu, X., Fu, Z., Tan, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26581265
Zhang, D.-Y., Wenqing, C., Hou, L., Yang, J., Lyu, L.-Y., Wang, Z.-Y., Linghu, K.-G., He, W.-B., Yu, H., & Hu, Y.-J. (2024) · Figshare · doi:10.6084/m9.figshare.26593283
Self-citationLaponogov, I., Gonzalez, G., Shepherd, M., Qureshi, A., Veselkov, D. A., Charkoftaki, G., Vasiliou, V., Youssef, J., Mirnezami, R., Bronstein, M. M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13514029
Gualdi, F. (2024) · Repositori digital de la UPF (Universitat Pompeu Fabra)
Data science and databases in drug discovery: technical development and applications
Ang, L., & Song, E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34059-8.00005-1
Roshan, R. P., Swetha, K., & Vimala, M. (2026) · Lecture notes in networks and systems · doi:10.1007/978-981-96-9935-3_14
Pinero, S. L., Li, X., Liu, L., Li, J., Lee, S., & Le, T. D. (2026) · medRxiv · doi:10.64898/2026.04.12.26350701
Jurowski, K., Niżnik, Ł., Noga, M., Kobylarz, D., Frydrych, A., Fijałkowska, O., Nepovimová, E., & Kuča, K. (2026) · Archives of Toxicology · doi:10.1007/s00204-026-04379-y
“Its integration of regulatory data ensures that all information reflects the most current standards and recom - mendations, which is crucial for maintaining patient safety in an ever evolving healthcare landscape (Ursu et al. 2017 ).”
Multi-view semi-supervised adversarial attention network for drug repurposing
Fan, M., He, D., Liu, Q., Liu, Q., Wang, F., Li, H., Wang, H., Shan, S., Zhang, J., & Hou, Y. (2026) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2026.109406
Mittal, A., Rani, P., & Jain, A. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c03157
GenesetDiseaseDrugNetwork (GDDN): a web server for disease enrichment and drug prioritizationPreprint
More, P. A., Fontaine, J., ten Cate, V., Wild, P. S., & Andrade-Navarro, M. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.22.727145
“There are databases like DrugCentral (Ursu et al. 2017), DrugBank (Knox et al. 2024), and ChEMBL (Bento et al. 2014) for connecting diseases or gene targets to drugs.”
Systems biology-based drug repurposing for neuroinflammation treatment in activated human microglia
Cirinciani, M., Germelli, L., Pozzo, E. D., Priami, C., Martini, C., & Milazzo, P. (2026) · Scientific Reports · doi:10.1038/s41598-026-56079-3
Fan, B., Wei, X., Li, W., Cui, S., Wang, X., Cui, J., Wang, X., Cong, W., Pan, M., Zheng, Q., et al. (2026) · Organic & Biomolecular Chemistry · doi:10.1039/d6ob00814c
Neri, A., Rotili, A., Morrocchi, E., Pascucci, G. R., Pighi, C., Olivieri, G., Betto, F., Emili, E., Karmakar, R., Iaconis, D., et al. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.00407-26
“EXDII is a proprietary Exscalate tool devoted to automatic integration of comprehensive up-to-date drug information collected from public and private databases (Cortellis Drug Discovery Intelligence by Clarivate (32); DrugCentral (33, 34), and ChemBL (35, 36).”
AI-Driven Drug–Target Interaction Prediction: From Data Representation to Model Design
Hu, J., Wu, L., He, S., Bo, X., & Lu, J. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c01920
A manufacturer-aware cross-system benchmark for pediatric pharmacovigilance signal concordance
Shi, J., Xia, J., Li, H., Zhang, S., & Shi, B. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1900271
“…target and Reactome indicators used ChEMBL and DrugCentral evidence available before 2021, where dates were present (WHO Collaborating Centre for Drug Statistics Methodology, 2026; Rogers and Hahn, 2010; RDKit Developers, 2026; Mendez et al., 2019; Ursu et al., 2017; Gillespie et al., 2022).”
Hodges, F., Bazarkulov, A., Koslicki, D., Roach, J. C., & Ramsey, S. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.29.755063
“5-labeled concepts, we extracted from DrugCentral [Ursu et al., 2017] a moderate-size (but high-confidence) set of negative (‘specific’) concepts.”
IMPPAT 3.0: An updated FAIR database of phytochemicals and formulations of Indian Medicinal plantsPreprint
Baskaran, S. P., Sahoo, A. K., Sil, P., Tiwari, R., Chivukula, N., Eapen, S. E., Ranganathan, G., Semwal, P., & Samal, A. (2026) · arXiv (Cornell University) · doi:10.48550/arxiv.2610.07478
ELROND: A Resistance Distance Based Approach to Ranking Results from Knowledge Graph Queries
Mesbah, A., Bizon, C., Sakaguchi, R. T., Tropsha, A., Wang, M., Wang, P., & Morton, K. D. (2026) · Communications in computer and information science · doi:10.1007/978-3-032-28454-9_11
Lee, C. G., Park, S., Lee, G. S., Moon, H. J., Choi, J., Lee, J. B., Martínez‐Sobrido, L., Almazán, F., Ryu, E.-H., Baek, Y., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219637
Integrative drug discovery for Parkinson’s disease with DIMERPreprint
Guo, S., Yang, X., Dong, Y., Yu, L., Sangjizhuoma, A., Sie, K. L., Zhu, K., Zhang, Y., Zhao, X., Kerman, E., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.28.762666
Kelch, M. A., Vera-Guapi, A., Beder, T., Oswald, M., Hiemisch, A., Beil, N., Wajda, P., Ciesek, S., Erfle, H., Toptan, T., et al. (2023) · doi:10.3389/fmicb.2023.1193320.s002
Koniuszewski, F., Vogel, F. D., Dajić, I., Seidel, T., Kunze, M., Willeit, M., & Ernst, M. (2023) · doi:10.3389/fpsyt.2023.1188101.s003
Peer review history of Polypharmacology guided drug repositioning approach for SARS-CoV2 (part 3)
Jamir, E., Sarma, H., Priyadarsinee, L., Kiewhuo, K., Nagamani, S., & Sastry, G. N. (2023) · doi:10.1371/journal.pone.0289890.r003
Rankin, K. A., Mei, F., Kim, K., Shen, Y. A., Sylvester, S., Fung, A., Gallo, V., Fancy, S. P. J., & Green, P. E. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.1475-18.2019
Metadata
- Authors
- Ursu, O., Holmes, J., Knockel, J., Bologa, C. G., Yang, J. J., Mathias, S. L., Nelson, S. J., & Oprea, T. I.
- Affiliations
- University of New Mexico (US)
- Corresponding author
- Oprea, Tudor I.
- ORCID
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-10-26
- Volume
- 45
- Issue
- D1
- Pages
- D932-D939
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC5210665
- OpenAlex
- W2539985226
- Cited by
- 323
- References
- 29
- Citations by year
- 2026: 23 · 2025: 39 · 2024: 34 · 2023: 39 · 2022: 26 · 2021: 31 · 2020: 45 · 2019: 40 · 2018: 27 · 2017: 17 · 2016: 2
- FWCI
- 26.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UNM’s Digital Repository (University of New Mexico) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- European Bioinformatics Institute
- National Institutes of Health
- U.S. Food and Drug Administration
- National Cancer Institute (U54CA189205, P30CA118100)
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- pharmacopoeia, active pharmaceutical ingredients, FDA-approved drugs, drug labels, drug-target interactions, pharmacological activity, drug indications, drug formulation, text mining, drug adverse events
- MeSH terms
- Drug Compounding, Drug Interactions, Drug Labeling, Pharmaceutical Preparations, Humans, United States, United States Food and Drug Administration, Drug Approval, Search Engine, Databases, Pharmaceutical, Drug-Related Side Effects and Adverse Reactions, Web Browser
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.